Måndag 3 Augusti | 05:21:51 Europe / Stockholm
Est. tid*
2026-10-22 08:00 Kvartalsrapport 2026-Q3
2026-07-16 - Kvartalsrapport 2026-Q2
2026-05-13 - X-dag ordinarie utdelning BONEX 0.00 SEK
2026-05-12 - Årsstämma
2026-04-22 - Kvartalsrapport 2026-Q1
2026-02-24 - Bokslutskommuniké 2025
2025-10-23 - Kvartalsrapport 2025-Q3
2025-07-15 - Kvartalsrapport 2025-Q2
2025-05-28 - X-dag ordinarie utdelning BONEX 0.00 SEK
2025-05-27 - Årsstämma
2025-04-24 - Kvartalsrapport 2025-Q1
2025-02-25 - Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-07-11 - Kvartalsrapport 2024-Q2
2024-05-17 - X-dag ordinarie utdelning BONEX 0.00 SEK
2024-05-16 - Årsstämma
2024-04-25 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-10-26 - Kvartalsrapport 2023-Q3
2023-07-13 - Kvartalsrapport 2023-Q2
2023-05-19 - X-dag ordinarie utdelning BONEX 0.00 SEK
2023-05-17 - Årsstämma
2023-04-27 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-10-27 - Kvartalsrapport 2022-Q3
2022-07-14 - Kvartalsrapport 2022-Q2
2022-05-20 - X-dag ordinarie utdelning BONEX 0.00 SEK
2022-05-19 - Årsstämma
2022-05-04 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-07-15 - Kvartalsrapport 2021-Q2
2021-05-21 - X-dag ordinarie utdelning BONEX 0.00 SEK
2021-05-20 - Årsstämma
2021-05-06 - Kvartalsrapport 2021-Q1
2021-02-17 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-17 - Kvartalsrapport 2020-Q2
2020-05-20 - X-dag ordinarie utdelning BONEX 0.00 SEK
2020-05-19 - Årsstämma
2020-05-08 - Kvartalsrapport 2020-Q1
2020-02-26 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-07-25 - Kvartalsrapport 2019-Q2
2019-05-15 - X-dag ordinarie utdelning BONEX 0.00 SEK
2019-05-14 - Årsstämma
2019-05-02 - Kvartalsrapport 2019-Q1
2019-02-27 - Bokslutskommuniké 2018
2018-11-07 - Kvartalsrapport 2018-Q3
2018-07-26 - Kvartalsrapport 2018-Q2
2018-05-23 - X-dag ordinarie utdelning BONEX 0.00 SEK
2018-05-22 - Årsstämma
2018-05-04 - Kvartalsrapport 2018-Q1
2018-02-20 - Bokslutskommuniké 2017
2017-11-02 - Kvartalsrapport 2017-Q3
2017-08-17 - Kvartalsrapport 2017-Q2
LandSverige
ListaLarge Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Bonesupport är verksamt inom medicinteknikbranschen och fokuserar på utveckling och tillverkning av biokeramiska implantat för benreparation och rekonstruktion. Bolagets produkter riktar sig till kirurger och sjukvårdsinstitutioner. Verksamheten är global med en huvudsaklig närvaro i Europa, Nordamerika och Asien. Bonesupport grundades år 1999 och har sitt huvudkontor i Lund.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

BONESUPPORT HOLDING AB (publ) – publishes Q2 2026 interim report

2026-07-16 08:00:00

BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the second quarter 2026.

"Strong growth and improved operating result with significant room for expansion for many years to come." Torbjörn Sköld, CEO

APRIL - JUNE 2026

  • Net sales increased by 25 percent (30 percent at constant exchange rates) and amounted to SEK 355.7 million (284.4).
  • The US segment reported a sales growth of 25 percent (31 percent at constant exchange rate).
  • The Europe & Rest of the World (EUROW) segment reported a sales growth of 24 percent (26 percent at constant exchange rates).
  • The gross margin amounted to 90.8 percent (92.3).
  • The adjusted operating result amounted to SEK 104.1 million (62.4). The reported operating result amounted to SEK 89.6 million (54.9).
  • Earnings per share before dilution were SEK 1.24 (0.81).
  • Earnings per share after dilution were SEK 1.23 (0.79).

JANUARY - JUNE 2026

  • Net sales increased by 20 percent (31 percent at constant exchange rates) and amounted to SEK 679.7 million (568.0).
  • The US segment reported a sales growth of 20 percent (33 percent at constant exchange rate).
  • The Europe & Rest of the World (EUROW) segment reported a sales growth of 16 percent (21 percent at constant exchange rates).
  • The gross margin amounted to 91.5 percent (92.5).
  • The adjusted operating result amounted to SEK 189.0 million (102.1). The reported operating result amounted to SEK 161.7 million (84.5).
  • Earnings per share before dilution were SEK 2.05 (0.96).
  • Earnings per share after dilution were SEK 2.03 (0.95).


EVENTS DURING THE QUARTER

  • In April, the US Centers for Medicare & Medicaid Services (CMS) published its proposed rule for the Medicare Inpatient Prospective Payment System (IPPS) for the fiscal year 2027. The proposal includes changes that improve payments for the use of CERAMENT G in the treatment of complex orthopedic infections, such as periprosthetic joint infection (PJI), fracture related infections, and diabetes related bone infection (diabetic foot). Final ruling is expected towards the end of the summer.
  • In May, the Company published its VSME Sustainability report for 2025.
  • In May, the Company hosted a Capital Markets Day for analysts, investors and media.
  • In June, the Company repurchased 373,320 own ordinary shares in agreement with a decision by the Annual General meeting on May 12, 2026. The buy-back program was carried out for the purpose of ensuring the Company’s obligations arising from the long-term share savings program LTI 2026 resolved by the Annual General Meeting on May 12, 2026.

EVENTS AFTER THE PERIOD

  • Adjustment of the guidance for 2026 to a sales growth of between 33-36 percent in constant exchange rates (previous guidance was a sales growth of more than 35 percent in constant exchange rates).